Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 463 clinical trials
TCD Followed by autoSCT for Newly Diagnosed MM Patients

Multiple Myeloma is a incurable disease. Thalidomide in combination with other agents are currently in trials for the newly diagnosed patients, we designed treatment of TCD, followed by

high dose chemotherapy
thalidomide
maintenance therapy
cell transplantation
  • 5 views
  • 07 Nov, 2020
  • 1 location
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

first line treatment for the patients with multiple myeloma 2. Secondary Objectives 1. To assess the progression free survival, duration of response, and overall

dexamethasone
induction therapy
velcade
platelet count
thalidomide
  • 7 views
  • 07 Nov, 2020
  • 1 location
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Myeloma. The second phase of the study will establish whether depsipeptide, bortezomib and dexamethasone is effective in the treatment of patients with multiple myeloma. The study will also

serum calcium
maintenance therapy
growth factor
monoclonal protein
neutrophil count
  • 31 views
  • 07 Nov, 2020
  • 1 location
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

CART therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with high risk multiple myeloma after

  • 37 views
  • 29 May, 2021
  • 1 location
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple

  • 4 views
  • 07 Jun, 2021
  • 12 locations
Study of SubQ Dara With Dose-Attenuated Bortezomib Lenalidomide Dexamethasone in Elderly NDMM

This is a single center, open-label, phase 2 study in elderly (age 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous

  • 1 views
  • 28 Jan, 2021
  • 1 location
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors Immunomodulators and Anti-CD38 Antibody.

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti

  • 0 views
  • 26 Jan, 2021
  • 5 locations
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction Follow by Dara Consolidation

The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo. Nevertheless, until now four

  • 0 views
  • 22 Jan, 2021
  • 1 location
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.

  • 0 views
  • 26 Jan, 2021
  • 1 location
  • 0 views
  • 26 Jan, 2021
  • 1 location